scholarly journals The diagnosis and treatment of papillary cystadenoma of the esophagus by the Endoscopy : a case report and literature review

2021 ◽  
Author(s):  
Zhaomeng Zhuang ◽  
Yiguang Zhang ◽  
Min Xie ◽  
Shuo Chen
Keyword(s):  
Age Of Onset ◽  
Submucosal Tumor ◽  
Clinical Manifestations ◽  
Diagnosis And Treatment ◽  
Esophageal Mucosa ◽  
Basal Cells ◽  
Course Of Disease ◽  
Papillary Cystadenoma ◽  
Long Course ◽  
Solid Lesions

Papillary cystadenoma is a epithelial benign tumor of the salivary gland, most commonly in the oral cavity, head and neck. There was no difference in the sex distribution of patients, and the age of onset was 30-50 years old. The clinical manifestations are: slow growth local mass, long course of disease, some can be as long as decades, most patients have no obvious conscious symptoms, a few patients can appear local pain or distension. However, papillary cystadenoma of the esophagus is very rare, and few cases have been reported. We report a case of papillary cystadenoma of the lower esophagus and its treatment by endoscopy. The patient had no obvious complaint of discomfort. Routine gastroscopy found submucosal protuberant lesions in the lower segment of the esophagus (Figure 1), and endoscopic ultrasonography suggested cystic and solid lesions originating from the muscular layer of the esophageal mucosa, thus mesenchymal tumor was preliminarily diagnosed (Figure 2). After the exclusion of relevant contraindications, preoperative examinations were completed and the tumor was completely removed by esophageal submucosal tumor excision under endoscopy (Figure 3). Postoperative pathology indicated the tumor is papillary cystadenoma, and immunohistochemistry indicated that: CK7(+), CK(+), and basal cells of P63 (+) (Figure 4, 5). Due to the rare case, combined with the process of the diagnosis and treatment of this case, we reviewed the relevant reports on the papillary cystadenoma of the digestive tract in the past 60 years, in order to help clinicians to improve their understanding and treatments of the papillary cystadenoma.

Gottron’s carcinoid papillomatosis of skin (features of clinical course, diagnosis and treatment, own clinical observation)

2021 ◽  
pp. 15-20
Author(s):  
T.О. Lytynska ◽  
O.V. Demchenko
Keyword(s):  
Clinical Observation ◽  
Clinical Course ◽  
Correct Diagnosis ◽  
Clinical Manifestations ◽  
Pathological Process ◽  
Current Data ◽  
Diagnosis And Treatment ◽  
Rational Approach ◽  
Significant Regression ◽  
Long Course

Objective — to study the features of the clinical course, diagnosis and rational approach to the treatment of Gottron’s carcinoid papillomatosis of skin.Materials and methods. The article presents current data on the clinical course, pathomorphological criteria, diagnosis and treatment of Gottron’s carcinoid papillomatosis of skin. The authors’ own clinical observation is given.Results and discussion. Gottron’s carcinoid papillomatosis of skin is dermatosis that is quite rare in medical practice. The disease is characterized by a long course with a permanent progression of the pathological process. In the vast majority of patients, this pathology develops against the background of other chronic dermatoses such as psoriasis, eczema, lichen planus, pemphigus. In addition, these patients are diagnosed with concomitant multiorgan somatic pathology, which causes not only severe course and recurrence of this dermatosis, but also requires a comprehensive approach to the treatment of these patients, taking into account the identified somatic pathology.Conclusions. Gottron’s carcinoid papillomatosis of the skin is characterized by a long course against the background of permanent progression of the pathological process.Treatment of patients with Gottron’s carcinoid papillomatosis should be comprehensive and individualized, taking into account the severity of dermatosis and concomitant pathology, which is predominantly multiorgan in nature and in some cases causes severe dermatosis and resistance to traditional therapy. This clinical case indicates a significant regression of clinical manifestations of dermatosis in patients with long­term disease, provided the correct diagnosis and adequate therapy.

A glance on dystonias, how to recognize and handle them

2019 ◽  
pp. 22-29
Author(s):  
F. N. Mercan ◽  
E. Bayram ◽  
M. C. Akbostanci
Keyword(s):  
Differential Diagnosis ◽  
Movement Disorder ◽  
Age Of Onset ◽  
Clinical Manifestations ◽  
Body Part ◽  
Classification Model ◽  
Treatment Choices ◽  
Muscle Groups

Dystonia refers to an involuntary, repetitive, sustained, painful and twisting movements of the affected body part. This movement disorder was first described in 1911 by Hermain Oppenheim, and many studies have been conducted to understand the mechanism, the diagnosis and the treatment of dystonia ever since. However, there are still many unexplained aspects of this phenomenon. Dystonia is diagnosed by clinical manifestations, and various classifications are recommended for the diagnosis and the treatment. Anatomic classification, which is based on the muscle groups involved, is the most helpful classification model to plan the course of the treatment. Dystonias can also be classified based on the age of onset and the cause. These dystonic syndromes can be present without an identified etiology or they can be clinical manifestations of a neurodegenerative or neurometabolic disease. In this review we summarized the differential diagnosis, definition, classifications, possible mechanisms and treatment choices of dystonia.

Clinical manifestations, diagnosis and treatment of HIV infection of stage 4 (severely symptomatic stage) in the practice of a health professional

2020 ◽  
pp. 27-34
Author(s):  
A. Nikitina ◽  
A. Rusanova ◽  
A. Zhilenkova
Keyword(s):  
Hiv Infection ◽  
Health Professional ◽  
Clinical Picture ◽  
Clinical Manifestations ◽  
Significant Problem ◽  
Diagnosis And Treatment ◽  
Modern World ◽  
Infected People ◽  
Stage 4 ◽  
Future Practice

HIV infection is a significant problem in the modern world, because there are more and more infected people every year. This article will consider: the clinical picture, diagnosis and treatment of this disease in different countries. Based on these data, the following conclusions will be made to help doctors in their future practice correctly approach the diagnosis and treatment of patients with this disease.

Adult systemic lupus erythematosus in Egypt: The nation-wide spectrum of 3661 patients and world-wide standpoint

Lupus ◽  
2021 ◽  
pp. 096120332110142
Author(s):  
Tamer A Gheita ◽  
Rasha Abdel Noor ◽  
Esam Abualfadl ◽  
Osama S Abousehly ◽  
Iman I El-Gazzar ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Age Of Onset ◽  
Wide Spectrum ◽  
Age At Onset ◽  
Disease Onset ◽  
Clinical Manifestations ◽  
Population Based ◽  
Systemic Lupus ◽  
Cross Sectional

Objective The aim of this study was to present the epidemiology, clinical manifestations and treatment pattern of systemic lupus erythematosus (SLE) in Egyptian patients over the country and compare the findings to large cohorts worldwide. Objectives were extended to focus on the age at onset and gender driven influence on the disease characteristics. Patients and method This population-based, multicenter, cross-sectional study included 3661 adult SLE patients from Egyptian rheumatology departments across the nation. Demographic, clinical, and therapeutic data were assessed for all patients. Results The study included 3661 patients; 3296 females and 365 males (9.03:1) and the median age was 30 years (17–79 years), disease duration 4 years (0–75 years) while the median age at disease onset was 25 years (4–75 years). The overall estimated prevalence of adult SLE in Egypt was 6.1/100,000 population (1.2/100,000 males and 11.3/100,000 females).There were 316 (8.6%) juvenile-onset (Jo-SLE) and 3345 adult-onset (Ao-SLE). Age at onset was highest in South and lowest in Cairo (p < 0.0001). Conclusion SLE in Egypt had a wide variety of clinical and immunological manifestations, with some similarities with that in other nations and differences within the same country. The clinical characteristics, autoantibodies and comorbidities are comparable between Ao-SLE and Jo-SLE. The frequency of various clinical and immunological manifestations varied between gender. Additional studies are needed to determine the underlying factors contributing to gender and age of onset differences.

scholarly journals A short review on leptospirosis: Clinical manifestations, diagnosis and treatment

2021 ◽  
Vol 11 ◽  
pp. 100741
Author(s):  
Chinju Susan Chacko ◽  
Shravya Lakshmi S ◽  
Anjali Jayakumar ◽  
Steffy Ligi Binu ◽  
Ramesh Datta Pant ◽  
...  
Keyword(s):  
Clinical Manifestations ◽  
Short Review ◽  
Diagnosis And Treatment

scholarly journals AB1045 CLINICAL, ANALYTICAL AND RADIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS WITH SARCOIDOSIS.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1814.2-1814
Author(s):  
I. Madroñal García ◽  
C. Aguilera Cros ◽  
L. Mendez Diaz
Keyword(s):  
Systemic Disease ◽  
Immunosuppressive Treatment ◽  
Clinical Manifestations ◽  
Corticosteroid Treatment ◽  
Pulmonary Involvement ◽  
List Type ◽  
Chi Square ◽  
Course Of Disease ◽  
Chronic Course ◽  
Radiological Stage

Background:Sarcoidosis is a systemic disease whose etiology is unknown. It is characterized by the formation of granulomas in any tissue of the organism. Ganglionic, pulmonary and cutaneus involvement is the most prevalent.Objectives:Describe clinical characteristics of a cohort of patients with sarcoidosis diagnosed.Define the association between the ACE’s number at diagnosis, radiological lung stage, treatment and course of disease.Evaluate if the extrapulmonary involvement is related to the course of the disease.Methods:Descriptive retrospective study of patients with S diagnosis treated in our Hospital in 2019. Data were obtained by reviewing medical records. Chi-square tests and parametric tests have been used to establish the differences described in the objectives.Results:102 patients diagnosed with sarcoidosis have been included, (51% females) with an average age of 56±11 years. Suspected diagnosis at the onset of disease was S in 70.6% of patients, followed by suspected lymphoma (20.6%). The average time for the definitive diagnosis of S was 9.5 months. 70.6% of the patients had elevated ACE titles at the beginning. Regarding the clinical manifestations, 18.6% of the patients presented fever at the beginning and 66.7% extrathoracic clinical manifestations. 72.5% have lymph node adenopathies, and in 91% there is thoracic involvement (the most frequent pulmonary stage is stage II). A biopsy was performed in 84.3% of the patients, the lung biopsy being the most performed (52.3%). 88.2% of patients received corticosteroid treatment at the onset of the disease (currently under treatment with corticosteroids 37.3%). 50% of patients are treated with immunosuppressants, Methotrexate was the most used. 5 patients are treated with biological therapy (AntiTNF).Regarding the course of the disease, 51% of the patients have a chronic course, 45.1% are in remission and 3.9% have suffered a relapse of the disease. In this study, no significant relationship was found between the ACE values at the onset of the disease, the pulmonary stage and the course of the disease.According to our data, patients presenting with extrathoracic clinical manifestations need more frequently corticosteroid treatment (p = 0.017) and immunosuppressive treatment (p = 0.001) with respect to patients who do not have an extrathoracic clinic. In addition, patients with an extrathoracic clinic present more frequently a chronic course of the disease than those who do not (p = 0.019).Conclusion:The results described in this study are similar to those found in the literature. The differences found can be explained because patients presenting with extrathoracic clinical manifestations have a more complicated management and need more treatment than those with only pulmonary involvement, even patients with radiological stage I do not usually need treatment, only surveillance.Disclosure of Interests:None declared

Pulmonary edema following scorpion envenomation: Mechanisms, clinical manifestations, diagnosis and treatment

2013 ◽  
Vol 162 (2) ◽  
pp. 86-91 ◽  
Author(s):  
Mabrouk Bahloul ◽  
Anis Chaari ◽  
Hassen Dammak ◽  
Mohamed Samet ◽  
Kamilia Chtara ◽  
...  
Keyword(s):  
Pulmonary Edema ◽  
Clinical Manifestations ◽  
Diagnosis And Treatment ◽  
Scorpion Envenomation

Mucolipidosis Type IV: Clinical Spectrum and Natural History

PEDIATRICS ◽  
1987 ◽  
Vol 79 (6) ◽  
pp. 953-959
Author(s):  
Naomi Amir ◽  
Joel Zlotogora ◽  
Gideon Bach
Keyword(s):  
Age Of Onset ◽  
Clinical Manifestations ◽  
Psychomotor Retardation ◽  
Clinical Spectrum ◽  
Lysosomal Storage ◽  
Mucolipidosis Type Iv ◽  
Type Iv ◽  
First Year Of Life ◽  
Developmental Features ◽  
Mucolipidosis Type

The clinical spectrum and developmental features of mucolipidosis type IV, a recessive lysosomal storage disorder, are presented. The evaluation was based on information from the clinical charts and information obtained from the families of 20 patients between the ages of 2 to 17 years. The clinical manifestations of the disease, profound psychomotor retardation and visual impairment, appear during the first year of life. Definitive diagnosis is made by electron microscopy which reveals storage organelles typical of the mucolipidoses. This study details, for the first time, the heterogeneity of the ophthalmologic features, specifically as pertains to the age of onset, degree and clinical course of the corneal opacities, and the retinal involvement. Although the top developmental level was found to be 12 to 15 months in language and motor function, the course of the disease is protracted for some children, who show only a slight improvement, and others, little if any deterioration despite the early infantile onset of the disease. This presentation provides guidelines for the clinical diagnosis of mucolipidosis type IV.

Pain in dementia

2021 ◽  
Vol 26 (3) ◽  
pp. 15-22
Author(s):  
T. M. Manevich ◽  
E. A. Mkhitaryan
Keyword(s):  
Pain Relief ◽  
Life Expectancy ◽  
Elderly Patients ◽  
Clinical Manifestations ◽  
Pain Syndrome ◽  
Diagnosis And Treatment ◽  
Prevalence Of Pain

Increasing life expectancy of the world’s population is accompanied by increasing number of elderly patients with dementia. According to various studies, the prevalence of pain syndrome in elderly patients with dementia ranges from 35.3% to 63.5%. The review represents data on the epidemiology, clinical manifestations, methods of diagnosis and treatment of pain syndrome in patients with dementia. Medicinal and non-pharmacological methods of pain relief are discussed.

Sign in / Sign up

Export Citation Format

Share Document